Delivery Order SPE2DB22D1017-SPE2DB25FYPZC
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pens valued at $8,763.90. This contract represents a firm fixed-price delivery order with an ultimate completion date of July 29, 2025, and will be fulfilled at the contractor's Conshohocken, Pennsylvania facility. The award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's competitive...
- The Defense Logistics Agency awarded a $13,027.34 delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Zepbound (tirzepatide) 15 mg/0.5 ml pens, with an ultimate completion date of September 4, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen Drug...
- The Defense Logistics Agency awarded a delivery order valued at $14,950.78 to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Zepbound (tirzepatide) 15 mg/0.5 mL pen injectors. This competitively awarded, firm fixed-price contract is scheduled for completion by July 24, 2025, with performance taking place at AmerisourceBergen's corporate offices in Conshohocken, Pennsylvania. The contract represents a single delivery order issued under a larger procurement vehicle and carries...
- The Defense Logistics Agency awarded a $1,143.89 delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL injectable pens. This competitively awarded, firm fixed-price delivery order will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 21, 2025. No set-aside designation was applied to this award. This delivery order represents a child contract under...
- The Defense Logistics Agency awarded a $4,888.38 delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of Zepbound (tirzepatide) 12.5 mg/0.5 mL in pen form with an ultimate completion date of August 25, 2025. This competitive award, issued without set-aside designation, carries firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply contract vehicle with DLA. The product will be performed at the company's...
- The Defense Logistics Agency awarded a $5,834.04 delivery order to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of Zepbound (tirzepatide) 15 mg/0.5 ml pen injectors. This non-competitive, firm fixed-price delivery order is set to be completed by September 5, 2025, and will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of Zepbound (tirzepatide) 15 mg/0.5 ml pen injectors, with a contract ceiling value of $41,933.14. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was made through open competition. The place of performance is located in Conshohocken, Pennsylvania, with an ultimate completion date of September 3, 2025. This delivery order is a...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order on July 25, 2025, for supply of Zepbound (tirzepatide) 10 mg/0.5 mL pens with a ceiling value of $1,143.87. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of July 28, 2025, and will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical,...
- The Defense Logistics Agency awarded a delivery order valued at $35,643.13 to AmerisourceBergen Drug Corp for the supply of Zepbound (tirzepatide) 7.5 mg/0.5 mL pens on August 5, 2025, with an ultimate completion date of August 6, 2025. This competitive, firm fixed-price delivery order carries no set-aside designation and will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a single delivery order under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $11,057.47 to AmerisourceBergen Drug Corp for the supply of Zepbound (tirzepatide) 10 mg/0.5 ml pen injections on August 8, 2025. This firm fixed-price delivery order, with a completion date of August 11, 2025, was competitively awarded with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform work at its corporate office location in...
- SPE2DB22D1017Indefinite Delivery Contract
- SPE2DB22D1017-SPE2DB25FYPZCDelivery Order
The Defense Logistics Agency awarded a $21,713.14 delivery order to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pens. This competitively awarded, firm fixed-price contract was placed under a non-set-aside procurement and is scheduled for completion by September 5, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters and primary distribution operations. This delivery order operates as a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of medications and medical commodities to support military healthcare programs worldwide. The Zepbound procurement supports federal healthcare initiatives, with the product typically used in diabetes and weight management treatment protocols across Defense Health Agency and other government medical systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $21.7k | 9/4/25 |